References
- Hollstein M. C., Sidransky D., Vogelstein B., Harris C. C. P53 mutations in human cancer. Science 1991; 253: 49–53
- Bartek J., Iggo R., Gannon J., Lane D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893–900
- Gannon J. V., Greaves R., Iggo R., Lane D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBOJ. 1990; 9: 1595–1602
- Stephen C. W., Lane D. P. Mutant conformation of p53. J. Molec. Biol. 1992; 225: 577–583
- Hu G., Zhang W., Deisseroth A. B. P53 gene mutations in acute myelogenous leukemia. Br. J. Haematol. 1992; 81: 489–494
- Fenaux P., Preudhomme Quiquandon C. I., Jonveaux P., Lai J. L., Vanrumbeke M., Loucheux-Lefebvre M. H., Bauters F., Berger R., Kerckaert P. Mutations of the p53 gene in acute myeloid leukemia. Br. J. Haematol. 1992; 80: 178–183
- Zhang W., Hu G., Estey E., Hester J., Deisseroth A. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 1992; 7: 1645–1647
- Milner J., Cook A. The cellular tumor antigen p53: evidence for transformation-related, immunological variants of p53. Virology 1986; 154: 21–30
- Milner J. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature 1984; 310: 143–145
- Milner J., Watson J. V. Addition of fresh medium induces cell cycle and conformation changes in p53, a tumor suppressor protein. Oncogene 1990; 5: 1683–1690
- Williams G. T., Smith C. A., Spooncer E., Dexter T. M., Taylor D. R. Haemopoietic colony stimulating factors promote cell survival by suppressing aoptosis. Nature 1990; 343: 76–79
- Chen P. L., Scully P., Shew J.-Y., Wang J. Y. J., Lee W.-H. Phosphorylation of the retinoblastoma gene product is modulated during cell cycle and cellular differentiation. Cell 1989; 58: 1193–1198
- Buchkovich K., Duffy L. A., Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 1989; 58: 1097–1105
- De Caprio J. A., Ludlow J. W., Lynch D., Furukawa Y., Griffin J., Piwnica-Worms H., Huang C.-M., Livingston D. M. The product of the retinoblastomasusceptibility gene has properties of a cell cycle regulatory element. Cell 1989; 58: 1085–1095
- Zhang W., Hittelman W., Van N., Andreeff M., Deisseroth A. The phosphorylation of retinoblastoma gene product in human myeloid leukemia cells during cell cycle. Biochem. Biophys. Res. Commun. 1992; 184: 212–216
- Richards F. M., Watson A., Hickman J. A. Investigation of the effects of heat shock and agents which induces a heat shock response on the induction of differentiation of HL-60 cells. Cancer Res. 1988; 48: 6715–6720
- Yufu Y., Nishimura J., Ideguchi H., Nawata H. Enhanced synthesis of heat shock proteins and augmented thermotolerance after induction of differentiation in HL-60 human leukemia cells. FEBS Lett. 1990; 268: 173–176
- Zhang W., Drach J., Andreeff M., Deisseroth A. Proliferation of hematopoietic cells is accompanied by suppressed expression of heat shock protein 70. Biochem. Biophys. Res. Commun. 1992; 183: 733–738
- Lane D. P., Benchimol S. P53: oncogene or anti-oncogene?. Genes Develop. 1990; 4: 1–8
- Lubbert M., Miller C. W., Kahan J., Koeffler H. P. Expression, methylation, and chromatin structure of the p53 gene in untransformed and human T-cell leukemia virus type I-transformed human T-lymphocytes. Oncogene 1989; 4: 643–651
- Zhang W., Hu G., Deisseroth A. Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. Gene 1992; 117: 271–275
- Milner J. A conformation hypothesis for the suppressor and promoter functions of p53 in cell growth control and in cancer. Proc. R. Soc. London 1991; 245: 139–145
- Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by in-terleukin-6. Nature 1991; 352: 345–347